APA (7th ed.) Citation

Lin, S., Chanchlani, N., Carbery, I., Janjua, M., Nice, R., McDonald, T. J., . . . Goodhand, J. R. (2022). Understanding anti‐TNF treatment failure: Does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease? Alimentary Pharmacology & Therapeutics, 56(5), 783. https://doi.org/10.1111/apt.17089

Chicago Style (17th ed.) Citation

Lin, Simeng, et al. "Understanding Anti‐TNF Treatment Failure: Does Serum Triiodothyronine‐to‐thyroxine (T3/T4) Ratio Predict Therapeutic Outcome to Anti‐TNF Therapies in Biologic‐naïve Patients with Active Luminal Crohn's Disease?" Alimentary Pharmacology & Therapeutics 56, no. 5 (2022): 783. https://doi.org/10.1111/apt.17089.

MLA (9th ed.) Citation

Lin, Simeng, et al. "Understanding Anti‐TNF Treatment Failure: Does Serum Triiodothyronine‐to‐thyroxine (T3/T4) Ratio Predict Therapeutic Outcome to Anti‐TNF Therapies in Biologic‐naïve Patients with Active Luminal Crohn's Disease?" Alimentary Pharmacology & Therapeutics, vol. 56, no. 5, 2022, p. 783, https://doi.org/10.1111/apt.17089.